The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Blood

Volumn 118, Issue 19, 2011, Pages 5250-5254

  O'Hare, Thomas ^a,b,c   Zabriskie, Matthew S ^a,b   Eide, Christopher A ^a,b   Agarwal, Anupriya ^a   Adrian, Lauren T ^a,b   You, Huihong ^a   Corbin, Amie S ^a   Yang, Fei ^d   Press, Richard D ^d   Rivera, Victor M ^e   Toplin, Julie ^f   Wong, Stephane ^f   Deininger, Michael W ^c   Druker, Brian J ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e ARIAD PHARMACEUTICALS INC   (United States)

^f MolecularMD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MUTANT PROTEIN; PHOSPHOTRANSFERASE; DNA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME INACTIVATION; GENE INSERTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADULT; AGED; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETICS; INDEL MUTATION; MALE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; ONCOGENE; TUMOR CELL LINE;

ADULT; AGED; BASE SEQUENCE; CELL LINE, TUMOR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; INDEL MUTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; YOUNG ADULT;

EID: 81155151860     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-349191     Document Type: Article

References (26)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. (Pubitemid 36302244)
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. (Pubitemid 44903745)
3. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401. (Pubitemid 38938156)
4. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of wild-type and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-141. (Pubitemid 40248339)
5. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinibresistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505. (Pubitemid 40740783)
6. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-412.
7. Chan WW, Wise SC, Kaufman MD, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011;19(4):556-568.
8. Eide CA, Adrian LT, Tyner JW, et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011;71(9):3189-3195.
9. Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J, Albitar M. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009;121(1):27-31.
10. Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn. 2008;10(2):177-180. (Pubitemid 351428400)
11. Quigley N, Henley D, Hubbard R. Characterization of a novel frame shift mutation in BCR-ABL transcripts. J Mol Diagn. 2004;6(4):415-416. Abstract.
12. Chu SC, Tang JL, Li CC. Dasatinib in chronic myelogenous leukemia. N Engl J Med. 2006;355(10):1062-1063.
13. Sherbenou DW, Hantschel O, Turaga L, et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008;22(6):1184-1190. (Pubitemid 351833786)
14. Lee TS, Ma W, Zhang X, et al. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008;7(12):3834-3841.
15. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003;12(1):27-37. (Pubitemid 36945035)
16. Mahadeo KM, Cole PD. Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS [published correction appears in Blood. 2010;116:1017]. Blood. 2010;115(18):3852.
17. Tyner JW, Rutenberg-Schoenberg ML, Erickson H, et al. Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. Leukemia. 2009;23(7):1345-1348.
18. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 2000;289(5486):1938-1942.
19. Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem. 2002;277(35):32214-32219. (Pubitemid 34969036)
20. Nagar B, Hantschel O, Seeliger M, et al. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell. 2006;21(6):787-798. (Pubitemid 43376129)
21. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5(1):33-44. (Pubitemid 38089839)
22. Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003;112(6):859-871. (Pubitemid 36378887)
23. Hantschel O, Nagar B, Guettler S, et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 2003;112(6):845-857. (Pubitemid 36378886)
24. Santamaria I, Pitiot AS, Balbin M. ABL alternative splicing is quite frequent in normal population. Mol Cancer Ther. 2010;9(3):772. Letter.
25. Khorashad JS, Milojkovic D, Reid AG. Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue. Mol Cancer Ther. 2010;9(7):2152. Letter.
26. Gaillard JB, Arnould C, Bravo S, et al. Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib. Mol Cancer Ther. 2010;9(11):3083-3089.